All In Biotech

Drug Trial Radar · NCT02830230

"Performance of HPV DNA Test in Presence of Co-infection With Common RTIs"

Last checked: Nov 20, 2026Latest source record: Jul 12, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

508

Planned (sponsor's estimate)

Start

Jul 2016

Primary completion

Dec 2017

Study completion Jul 2018

Sponsor

Lead sponsor
Tata Memorial HospitalGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Jul 12, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Single group
Masking
Single (outcomes assessor)
Primary purpose
Screening
Who can join
Female only, from 30 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

There is a strong causal association between persisting genital tract infection with Human Papilloma Virus (HPV) and gradual progression of infection to cervical (mouth of uterus) cancer.The robust study from India have shown that single round of HPV DNA screening test to significantly reduce the cervical cancer mortality. The above findings are very encouraging since it demonstrates that a simple and reliable HPV DNA test which is now available in low income countries has a potential to be accepted as primary screening test in future. The cross-sectional studies from developed countries from year 1999-2004 which focused to determine the test characteristics of HPV Hybrid Capture 2 test (HC2) to determine CIN2 and higher grade lesions, reported test sensitivity of 90% to 100% with a mean of 95%. Similarly the cross-sectional studies from developing countries from 1993 to 2003 which have focused on test characteristics of HPV DNA Hybrid capture 2 (HC2) test to determine CIN2 and higher grade lesions has shown a sensitivity in the range of 50% to 91% with an average sensitivity of 79%.Among the developing countries cross-sectional study from India which evaluated test reported sensitivity of only 68.2%. There is a statistical significant difference ( p value = 0.003) of sensitivity of HPV DNA HC2 test between the developed and developing countries to determine CIN2+ Lesions while there is no difference in the specificity. A study that was conducted in Chinese women to detected the prevalence of HPV genotype among women with mucopurulent cervicitis, healthy women and women with Invasive cancer, the author reported a 10% higher failure rates to extract HPV DNA in cases of mucopurulent cervicitis as compared to other two groups. So the study will explore if if the presence of untreated co-infections with STIs/RTIs (Sexually transmitted infections/Reproductive tract infections) resulting in cervical inflammation is somewhere interfering with low sensitivity of HC2 test due to presence of blood and excess mucus associated with the conditions leading to low sensitivity of the test in context to Indian Scenario.

Conditions

  • Cervical Inflammation and Human Papilloma Virus Performance

Interventions

  • Tab cefixime,Tab AzithromycinDrug

    The women with clinical cervicitis will receive treatment for cervicitis.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference in the number of participants diagnosed with HPV infections before and after treating clinical cervicitisTime frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tata Memorial Hospital

    Mumbai, Maharashtra, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.